×

img Acces sibility Controls

Technologies Banner

Medical Sciences

Novel Antibiotic Against Colistin Resistant MDR Klebsiellasps

Implementing Organization

Institute of Microbial Technology (IMTECH)
Institute of Microbial Technology (IMTECH), Chandigarh

About

A drug specifically active againstK. pneumoniaestrains of clinical relevance may be used as a definitive therapy. The analogues of this compound which are more efficacious and less toxic can be patented and commercialized. Moreover, the technology for producing this natural compound using the producer microorganism itself in fermentation after media and process optimization can have commercial value. Alternatively, the biosynthetic genes for M152-P3 compounds can be cloned and expressed in a suitable host for large scale synthesis at cheaper scale.

Outcome / Output

The salient features of this technology are: The compound is novel , Active against colistin resistant MDR Klebsiellasps , The spectrum of activity is better than existing polymyxin B and colistin , It is bacterial fermentation based product , It is non-haemolytic and non-toxic , The chances of cross resistance is less as this scaffold/antibiotic is not in clinical practice at present
Quick Information
Thrust Areas
Medical Sciences
Focus Area
Antibiotic
Status
completed
Contact
director@imtech.res.in
Disclaimer: Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.
arrowtop
Latest Updates
Loading…